The Patent Finder

Intercept Pharmaceuticals, Inc.

27 patents currently held · Updated Nov 22, 2026
16 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 6, 2027
    The maintenance fee for Methods of treating cancer (US 10,369,160) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
  • 1 fee due May 7, 2027
    The maintenance fee for TGR5 Modulators and Methods of Use Thereof (US 11,807,659) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 2 fees due Aug 4, 2027
  • 1 fee due Sep 30, 2027
    The maintenance fee for Methods for preparation of bile acids and derivatives thereof (US 10,604,544) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
  • 1 fee due Nov 12, 2027
    The maintenance fee for Compositions of Obeticholic Acid and Methods of Use (US 10,646,499) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,546,365Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
In force
 · USPTO record
In forceUSPTO record
US 7,994,352Process for preparing 3a(β)-7a(β)-dihydroxy-6a(β)-alkyl-5β-cholanic acid
In force
 · USPTO record
In forceUSPTO record
US 7,932,244Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
In force
 · USPTO record
In forceUSPTO record
US 9,540,414TGR5 modulators and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 8,114,862TGR5 modulators and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 8,410,08323-substituted bile acids as TGR5 modulators and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 8,796,249TGR5 modulators and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 8,999,964TGR5 modulators and methods of use thereof
In force
 · USPTO record
In forceUSPTO record
US 9,777,038Process for preparing bile acid derivatives
In force
 · USPTO record
In forceUSPTO record
US 10,894,054FXR agonist compositions for combination therapy
In force
 · USPTO record
In forceUSPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 16 patents in force now held by others · 11 lapsed for an unpaid fee · 8 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 15 abandoned · 21 no status recorded

Showing 1 to 10 of 43, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/233,923Pharmaceutical Compositions for Combination TherapyJun 10, 2025Pending
19/233,916Jun 10, 2025No status recorded
19/198,431Farnesoid X Receptor ModulatorsMay 5, 2025Pending
18/800,808Farnesoid X Receptor ModulatorsAug 12, 2024Pending
18/436,527Feb 8, 2024No status recorded
18/878,533Methods for Ameliorating Cognitive Impairment Using Bile Acid DerivativesJun 30, 2023Pending
18/858,674Uses of Farnesoid X Receptor AgonistsApr 21, 2023Pending
18/295,091Farnesoid X Receptor ModulatorsApr 3, 2023Abandoned
18/188,341Preparation and Uses of Obeticholic AcidMar 22, 2023Abandoned
18/833,630Combination TherapyJan 30, 2023Pending
10 of 43 applications shown.
Pro members see all 43 published applications.
Pro members: see all 43 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited